Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075738 | 0.80 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL19639618 | 0.76 | GRM1 (0.37) | MEN1KMT2A | |
| SCHEMBL30885816 | 0.74 | ASGR1 (0.31) | — | |
| SCHEMBL19766525 | 0.73 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL30937226 | 0.73 | MEN1 (0.34) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27190969 | 0.71 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL12858008 | 0.71 | PKM (0.52) | MEN1KMT2A | |
| SCHEMBL19639606 | 0.70 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL19639612 | 0.70 | — | — | |
| SCHEMBL19639616 | 0.67 | SMN1; SMN2 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464275-B1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-12-23 | — | — | US | disclosed |
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | MEN1 2877/4885KMT2A 3296/4885 |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | MEN1 2877/4885KMT2A 3296/4885 |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | MEN1 2877/4885KMT2A 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.